CUMBERLAND PHARMACEUTICALS INC
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
CPIX$5.37+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $11,007,245 | $11,444,693 |
| Accounts receivable, net | 14,261,978 | 16,944,780 |
| Inventories, net | 5,453,836 | 6,225,518 |
| Prepaid and other current assets | 2,066,198 | 2,445,276 |
| Total current assets | 32,789,257 | 37,060,267 |
| Non-current inventories | 9,875,505 | 9,253,090 |
| Property and equipment, net | 237,375 | 264,724 |
| Intangible assets, net | 12,793,249 | 14,027,921 |
| Goodwill | 914,000 | 914,000 |
| Operating lease right-of-use assets | 7,618,720 | 8,343,832 |
| Co-commercialization investment | 3,840,700 | 3,986,780 |
| Other assets | 2,926,214 | 2,973,378 |
| Total assets | $70,995,020 | $76,823,992 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $16,537,072 | $18,567,546 |
| Operating lease current liabilities | 485,162 | 467,774 |
| Other investment liabilities | 4,487,137 | 5,074,504 |
| Other current liabilities | 12,978,680 | 12,635,095 |
| Total current liabilities | 34,488,051 | 36,744,919 |
| Revolving line of credit - long term | 5,240,733 | 5,240,733 |
| Operating lease non-current liabilities | 4,343,892 | 4,471,965 |
| Other long-term liabilities | 5,619,332 | 5,822,153 |
| Total liabilities | 49,692,008 | 52,279,770 |
| Equity: | ||
| Shareholders’ equity: | ||
| Common stock— no par value; 100,000,000 shares authorized; 14,983,107 and 14,956,627 shares issued and outstanding as of March 31, 2026, and December 31, 2025, respectively | 51,730,222 | 51,684,381 |
| Accumulated deficit | (30,093,698) | (26,804,059) |
| Total shareholders’ equity | 21,636,524 | 24,880,322 |
| Noncontrolling interests | (333,512) | (336,100) |
| Total equity | 21,303,012 | 24,544,222 |
| Total liabilities and equity | $70,995,020 | $76,823,992 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.